Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives

Title:Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives

Volume: 21 Issue: 1

Author(s): Juan J. Rodriguez, Oscar C. Munoz*, Mateo Porres-Aguilar and Debabrata Mukherjee

Affiliation:

• Department of Interventional Cardiology, Del Sol Medical Center, El Paso, TX 79925,United States

Keywords: COVID-19, thrombosis, thromboembolism, venous thromboembolism, thromboprophylaxis, bleeding, stroke, myocardial infarction, pulmonary embolism.

Abstract: The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.

Cite this article as:

Rodriguez J. Juan , Munoz C. Oscar *, Porres-Aguilar Mateo and Mukherjee Debabrata , Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (1) . https://dx.doi.org/10.2174/1871529X21666210315123347